Bioequivalence study comparing Zubsolv with Suboxone sublingual tablets
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid abuse
- Focus Pharmacokinetics; Registrational
- 18 Oct 2016 New trial record
- 04 Oct 2016 Results published in an Orexo media release.
- 04 Oct 2016 According to an Orexo media release, a Marketing Authorization Application (MAA) has been submitted for Zubsolv sublingual tablet to the EMA for the treatment of opioid dependence based on data from this trial.